Navigation Links
Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
Date:11/11/2008

("Raptor") is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. We focus on underserved patient populations where we can have the greatest potential impact. Raptor is currently running clinical trials in patients with aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH").

Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins to that are designed to target cancer, neurodegenerative disorders and infectious diseases.

For additional information, please visit http://www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: Raptor's ability to obtain Asian partners to further develop Convivia(TM); Raptor's ability to manufacture clinical scale quantities of its proprietary Convivia(TM) formulation; Convivia's(TM) ability to benefit ALDH2 deficient individuals by lessening their exposure to acetaldehyde and mitigating their unpleasant reactions to drinking; the ability of Convivia(TM) to be successfully developed into a marketable treatment; and Raptor's ability to successfully develop any of its other clinical and preclinical products. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our actual results to be materially different from these forward-looking statements. Factors which m
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
2. Raptor Pharmaceuticals Provides Update on Targeting Platforms
3. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
4. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
5. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
6. Raptor Pharmaceuticals Provides Update of Product Programs
7. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
8. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
9. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
10. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
11. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , December 19, 2014 TODAY, ... in the World announced the appointment of Peter ... Vonsée, as Chief Channels and Partner Officer. ... 2004 through to its acquisition by Oracle in 2011. ... at Geneva and subsequently Convergys, ...
(Date:12/19/2014)... Wash. , Dec. 19, 2014  Advanced ... stage development company engaged primarily in the development ... and therapeutic applications, today announced that a Life ... has been awarded for which AMIC is the ... State University (WSU) for the proposal titled "Optimized ...
(Date:12/19/2014)... HILL, N.C. , Dec. 19, 2014 /PRNewswire/ ... to optimize a product,s web presence to reflect ... Brand websites, in particular, must meet the needs ... regulations and culture. According to ... more than half of the participating companies averaged ...
Breaking Medicine Technology:Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Building a Best-in-Class Pharma Global Brand Website 2
... Trial Results Confirm Efficacy for Population Most ... and EMERYVILLE, Calif., May 16 ,Bayer HealthCare ... ONXX ) today announced that Nexavar(R) (sorafenib) ... (HR=0.68;,p-value=0.014) in patients in the Asia-Pacific region ...
... SAN FRANCISCO, May 15 Medivation, Inc.,(Nasdaq: MDVN ... 1-2 clinical,trial of its novel androgen receptor antagonist, MDV3100, ... American Society of Clinical Oncology,(ASCO) Annual Meeting in Chicago., ... with Prostate Cancer Session date and time: Monday, ...
Cached Medicine Technology:Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3
(Date:12/22/2014)... December 22, 2014 Fad diets ... The reason why most fad diets have hung around ... problem with fad diets is that, as the body becomes ... dieter uncertain of how to reset the metabolism to return ... Diet Doc developed their all-inclusive diet plans that ...
(Date:12/22/2014)... 2014 On December 22, 2014, My ... Gordon Cashwell for an episode to celebrate Christmas. At ... is it so important to you that we all ... “We all should respect who Jesus was. I think ... Christian beliefs. That means that on Jesus’ birthday we ...
(Date:12/22/2014)... 21, 2014 (HealthDay News) -- A new vaccine created ... in deer might also protect livestock and even humans ... appears to help prevent deer from becoming infected by ... according to the report in the Dec. 21 online ... disease is caused by mysterious infectious particles known as ...
(Date:12/22/2014)... December 22, 2014 Explorys, the leader ... to its leadership team: Greg Yarrington as Vice President ... and Patrick Wells as Vice President of Solutions. These ... 80 new jobs in 2015 to support client demand ... its platform-as-a-service offerings, and growth of its partner network. ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The MedTech industry ... Inc, a wholly owned subsidiary of PartnerTech AB of Sweden, ... having recently achieved additional ISO Certification. , All signs point ... employment and the likelihood of a repeal of the excise ... . The industry is anticipating annual growth of 9.3% and ...
Breaking Medicine News(10 mins):Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 4Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2Health News:Vaccine for Deer Against 'Mad Cow'-Like Illness Shows Promise 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:PartnerTech Inc. Poised for Growth in MedTech 2
... eggs to deteriorate in quality with age, and can that ... egg -- out of a stash of roughly one million ... be influenced to pick a "good" quality egg rather than ... much on the mind of fertility researcher Teresa Woodruff. Woodruff, ...
... a key protein might reap rewards for people ... (HealthDay News) -- Researchers have uncovered cellular proteins that ... according to a new study. , The findings, ... new treatments for a range of human diseases that ...
... WASHINGTON, June 19 Most seniors -,regardless ... Medicare or Medicare,Advantage - oppose cutting the ... payment fix and believe cuts to Medicare ... a new survey finds., Power Point ...
... Protections for Poor Beneficiaries, SAN FRANCISCO, June ... federal court today in the Medicare Part D ... has agreed to make,significant changes to its administration ... approved by the judge, the agreement will,make it ...
... DALLAS, June 19 Federal Reserve chairman Ben Bernanke,s,comments ... health care,system is one of the biggest challenges facing ... care costs will rise nearly 10 percent this,year, lend ... emphasis on,prevention and wellness, according to U.S. Preventive Medicine, ...
... Better Health offers members access to 75 generic drugs at no cost ... ... Independence Blue Cross (IBC),will waive copays and coinsurance on 75 generic drugs ... a member incentive,program designed to help our members become more actively involved ...
Cached Medicine News:Health News:New photo 'op' for ovaries may solve some mysteries of infertility 2Health News:Autoimmune Disease Treatment May Not Dampen Immune System 2Health News:Autoimmune Disease Treatment May Not Dampen Immune System 3Health News:Autoimmune Disease Treatment May Not Dampen Immune System 4Health News:Seniors Oppose Cutting Medicare Advantage to Fund Physician Payment Fix 2Health News:Bush Administration Settles Nationwide Class Action in Medicare Prescription Drug Case 2Health News:Bush Administration Settles Nationwide Class Action in Medicare Prescription Drug Case 3Health News:U.S. Preventive Medicine Views Bernanke's Comments as Strong Support for Prevention and Wellness Programs 2Health News:Independence Blue Cross Waives Copays for Generics Used to Treat Certain Chronic Conditions 2Health News:Independence Blue Cross Waives Copays for Generics Used to Treat Certain Chronic Conditions 3Health News:Independence Blue Cross Waives Copays for Generics Used to Treat Certain Chronic Conditions 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: